Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention

被引：23

作者：

Kereiakes, DJ

Broderick, TM

Whang, DD

Anderson, L

Fye, D

机构：

[1] OHIO HEART HLTH CTR, CINCINNATI, OH USA

[2] UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 1997年 / 80卷 / 05期

关键词：

D O I：

10.1016/S0002-9149(97)00437-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serious hemorrhage and vascular complications after abciximab therapy are associated with elevated activated clotting time values. Our preliminary experience suggests that low-dose intravenous protamine administration is both safe and effective in reducing elevated in-laboratory activated clotting time values and the potential for serious hemorrhage in abciximab-treated patients.

引用

页码：633 / +

页数：1

共 5 条

[1] In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time [J].

Ammar, T ;

Scudder, LE ;

Coller, BS .

CIRCULATION, 1997, 95 (03) :614-617

[2] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[3] Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization [J].

Lincoff, AM ;

Tcheng, JE ;

Califf, RM ;

Bass, T ;

Popma, JJ ;

Teirstein, PS ;

Kleiman, NS ;

Hattel, LJ ;

Anderson, HV ;

Ferguson, JJ ;

Cabot, CF ;

Anderson, KM ;

Berdan, LG ;

Musco, MH ;

Weisman, HF ;

Topol, EJ .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (03) :286-291

[4] EFFECT OF PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN BLOCKADE ON ACTIVATED CLOTTING TIME DURING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY OR DIRECTIONAL ATHERECTOMY (THE EPIC TRIAL) [J].

MOLITERNO, DJ ;

CALIFF, RM ;

AGUIRRE, FV ;

ANDERSON, K ;

SIGMON, KN ;

WEISMAN, HF ;

TOPOL, EJ .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (08) :559-562

[5]

STOELTING RK, 1983, ANESTH ANALG, V62, P341

← 1 →